It's Pi Day! 3.14! π! We've celebrated before, but this year we wanted to do something bigger. Don't get me wrong, we love baking and eating delicious pies, but have we waxed mathematical!? Well this year, CST's bravest of the brave ran our gauntlet of pi-related trivia! They didn't just eat pie, they earned it. Luckily, CST News anchor Jak Stat and the CST News team were live on the scene.
Topics: Just for fun
As a development scientist at CST, people sometimes ask me what exactly it is that I do. “I make antibodies,” is my typical reply, but that is not exactly true.
Topics: Antibody Validation
Let’s face it, we are an energy-intensive industry. From ultra low temperature freezers for storing products, to HVAC and lighting, plus lab equipment and fume hoods, it all adds up to a significant load. In 2017, CST’s two U.S. facilities used 7,677,140 kWh, which is the equivalent to the electrical consumption of 856 households! While creating that amount of energy on our own would require a golf course sized array of renewables, we can take steps to whittle down a percentage of energy consumption with solar panels on our roof.
Topics: Corporate Social Responsibility
Congratulations to our CEO and founder Dr. Michael J. Comb, whom CiteAb has selected for a lifetime achievement award. Dr. Comb likes fly-fishing in Alaska and rock climbing in Yosemite more than he likes the spotlight, but this award has given us the opportunity to acknowledge our fearless leader. CiteAb recognizes individuals from the research community for their dedication and contribution to the research reagent industry over a sustained period. Dr. Comb is being honored for his tireless efforts to build the best antibody technology in the world for researchers working to understand the molecular and cellular processes of disease.
Topics: Science Education
It’s Valentine’s Day. You can’t put out that bowl of candy hearts because…NO FOOD IN THE LAB!!! Okay, fair enough, but there has to be another way to send a message to someone special at the bench. Why not use antibodies to your advantage? The label of your vials might have all the messaging you need!
Topics: Just for fun
We as scientists learn from each success and failure. Sometimes it takes many failures to achieve success. And some discoveries are made with no fanfare, far from the spotlight. Other times, a good day’s work is even sweeter when you realize someone noticed!
So your experiments and data are funneling you down an inescapable path. You need to show direct gene regulation by your protein of interest. You think to yourself, “Oh, ChIP...”
Characterize Myeloid Cell Mediated Immunosuppression in the Tumor Microenvironment Using Multiplex IHC
The clinical validation of immune checkpoint inhibitors as immunotherapeutic agents for a variety of cancers has revolutionized the field of cancer therapy. While significant improvement in patient outcome has been observed with previously untreatable tumors, not all patients respond to these drugs (1). An advanced understanding of the immune regulatory context of the tumor microenvironment (TME) is required to harness the power of the antitumor immune response. This will allow identification of novel therapeutic targets and potential biomarkers that can predict response to therapy (2, 3).
Our mIHC application notes and poster resources explore the protocol and technical considerations for selecting and using antibodies in mIHC to assess immunosuppression mediated by myeloid cells in FFPE tissue samples.
Type 2 diabetes is a growing epidemic, and is recognized as one of the most serious metabolic disease worldwide. A multifactorial disease, type 2 diabetes is a perfect example of metabolic miscommunication between different organs resulting in a pathological outcome. According to CDC in the United States, 29.1 million people in the United States have diabetes, and 8.1 million may be undiagnosed. The disease affects more than 1 in every 10 adults, and seniors aged 65 and above are most affected. What makes the disease morbid are the secondary complications associated with it; atherosclerosis and cardiomyopathy are the leading cause of death in people diagnosed with type 2 diabetes. The need for an effective treatment has become a global health priority.
The importance of antibodies as tools in scientific research studies cannot be understated, yet these reagents have increasingly come under fire for their lack of reproducibility. Part of the issue is that the antibody market is composed of hundreds of vendors and resellers with varying definitions for validation and consistency. Cell Signaling Technology (CST) believes that antibody suppliers should be held accountable for the products they provide, but that vendors alone cannot solve the reproducibility “crisis." How antibodies are validated and used in the laboratory is a critical component to this process. Researchers need to be more attentive to following established protocols and leverage the expertise of the scientists who have developed and tested the product they are using. Journals need to be more active in enforcing existing policies regarding materials and methods or develop more clear-cut means to identify and describe the use of biological reagents in published research. During this webinar we will address the role vendors, researchers, and journals should play in minimizing irreproducibility. We will also outline CST’s antibody validation process, while highlighting steps all users should consider when selecting and using antibodies in their research.